Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO ...

Researchers conducted the IMPROVE trial to evaluate whether a 3-week pause in BTK inhibitor use would improve immunity after COVID-19 booster vaccination without negatively affecting disease control ...

Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than ...

Early Phase I results for JNJ-79635322 demonstrated an 86.1% overall response rate in heavily pretreated multiple myeloma ...

Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response ...

ASCO Annual Meeting highlighted key advances in brain cancer and brain metastases for patients affected by the disease.

The debate between CAR T-cell therapy and bispecific antibodies is not a rivalry but a question of sequencing, ...

The combo therapy demonstrated an ORR of 87%, with a complete response rate of 65% and a partial response rate of 23%.

Results from the Phase II VLA1553-221 trial show that a full dose of Ixchiq demonstrated a 96.5% seroresponse rate in ...

The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response rates for patients with blastic plasmacytoid dendritic cell neoplasm ...